Sponsor pipeline

QED Therapeutics, a BridgeBio company clinical trial pipeline

Get alerts when QED Therapeutics, a BridgeBio company's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

Active trials by phase

Phase 2
3
Phase 2/3
1
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2/3
NCT06873035 An Interventional Study of Infigratinib in Children With Hypochondroplasia Hypochondroplasia Enrolling by Invitation 2026-07-16
Phase 2
NCT07169279 Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) Achondroplasia Recruiting 2026-07-13
NCT07393373 Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia Hypochondroplasia Enrolling by Invitation 2026-08-26
NCT05145010 Extension Study of Infigratinib in Children With Achondroplasia (ACH) Achondroplasia Enrolling by Invitation 2025-10-31
Not specified
NCT06410976 Prospective Clinical Assessment Study in Children With Hypochondroplasia Hypochondroplasia Recruiting 2026-07-16
Get alerts when QED Therapeutics, a BridgeBio company's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free